Christopher Williams Email & Phone Number

Norwalk, Connecticut, US

• Direct all facets of business relationships with pharma, biotech, and technology partners to create continuing opportunities.
• Cultivate and maintain relationships with cross-functional partners, negotiate various contracts and deals.
• Oversee the technology development of an online patient-facing registry.
• Secured and completed multiple technology contracts in areas such as NGS, EMR/EHR extraction, AI analysis, mobile phlebotomy, and multiple outside consultants.
• Chair and administer various grant programs for both academic medical centers and technology partners.
• Maintain responsibility for managing ongoing relationships with top pharma and biotech partners in all areas, including research, patient education, and events.

• Spearheaded various business development efforts, including product support, market analysis, product menu expansion, and strategic partnerships.
• Collaborated with Sales to identify and gain an audience with leading labs for product introduction.
• Completed CE-IVD mark and registration of products in the EU and Turkey.
• Appraised and reviewed new and existing technologies for competitive analysis purposes.
• Remained abreast of the current disease markets, identified new biomarkers for potential product opportunities.
• Initiated and closed agreements for various business segments.

Rotterdam, Zuid-Holland, NL

• Headed US commercialization strategy for the Oncology Product portfolio.
• Identify and initiate CLIA laboratory implementation of products and services.
• Captured key research/clinical partnerships with leading academic/pharmaceutical laboratories.
• Devised and developed a comprehensive billing and reimbursement strategy for the US market.
• Establish scientific advisory board/KOL relationships/speaker board.
• Established world class SAB in Multiple Myeloma space

Shelton, CT, US

• Drove business development by establishing Oncology Market Strategy within the Diagnostics Division.
• Established operating plan goals for cancer diagnostics products, ranging from $500K – 1M.
• Launched hematological malignancy focused microarray platform (20+ new customers).
• Coordinated and executed various activities that included KOL interviews, reimbursement strategy, go to market readiness with cross-functional teams (clinical validation, marketing/sales, senior management), and sales.
• Collaborated with KOLs regarding product advocacy and education efforts.
• Presented product specific talks at meetings and NCI Cancer Centers (Grand Rounds/Tumor Boards).

Shelton, CT, US

• Tasked with technical/sales support for Molecular Diagnostics products.
• Assisted and supported customers and the sales organization in the area of Array Comparative Genomic Hybridization (CGH).
• Authored and published three application notes in 2008 (Applications: Stem Cells, Oncology, and Developmental Delay).
• Provided extensive customer support that included training, technical seminars, and troubleshooting (20+ seminars/year).

Shelton, CT, US

• Charged with applications support for Functional Genomic/Proteomic products.
• Published applications notes for piezoelectric printing and fluorescent scanners.
• Played a key role in R&D for product improvements on aCGH products.
• Incorporated the voice of customer interviews to define R&D product pipeline for array CGH products.
• Supervised assay development in the area of protein/peptide microarrays.
• Optimized conditions for piezoelectric deposition of antibodies on glass slides.

US

• Responsible for assay development in the area of protein/peptide microarrays
• Optimized conditions for piezoelectric deposition of antibodies on glass slides
• Developed sandwich type assays for the quantitative monitoring of key signal transduction proteins
• Responsible for SBIR phase I grant data and report submission as well as phase II proposal

Cambridge, MA, US

• Responsible for development and implementation of new technologies in the area of protein/protein interactions and proteomics, with an emphasis on biosensors
• Developed novel interface for the analysis of proteins bound to biosensor surfaces by mass spectrometry
• Developed novel assay for GPCR “de-orphaning” using biosensor surfaces and mass spectrometry. Allowed for the discovery of possible novel GPCR ligands in less than two months
• Developed assays that predicted the plasma binding properties of small molecules in a high throughput mode. Increased the number of drugs screened from 5-10 a week to 100 per day
• Prepared numerous intramural and extramural project proposals and gained corporate approval
• Participated in the assessment of the current and future needs for new technologies in the molecular validation of targets. Assisted in the design and implementation of ‘proof-of-concept’ studies

Basel, Basel-Stadt, CH

• Designed and validated high throughput assays for drug discovery in oncology.
• Developed assay platforms for target validation and screening of small molecules for oncology candidates (PCR, Cloning & Expression, IP & Western Blots).
• Introduced surface plasmon resonance biosensors as a tool for target validation and assay development Implemented Biacore® for use in mutation analysis of BCR/Abl binding peptides as well as kinetic analysis of lead.
• Assessed the current and future needs for new technologies in the molecular validation of targets and oversaw the design and implementation of the ‘proof-of-concept’ studies.

Kenilworth, New Jersey, US

• Functioned as a contributing member of the teams responsible for various research projects for drug development in tumor biology.
• Responsible for protein expression and purification for the RAS p21 project. Expressed in E. coli, baculovius, and mammalian cell lines.
• Set up in vitro and in vivo secondary assays to screen and validate lead compounds for ant-tumor activity.
• Small animal handling and surgery (mice, rats, and rabbits) for drug studies and antibody production.

Master Of Science - Ms, Biochemistry

Bachelor Of Science - Bs, Microbiology/Molecular Biology